The role of epidermal growth factor receptor inhibitor, gefitinib, in improvement of quality of life of patients with non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 8, Issue 4, 2005, Pages 313-316

  Mu, Xinlin ^a   Li, Longyun ^a   Zhang, Xiaotong ^a   Wang, Shulan ^a   Wang, Mengzhao ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Epidermal growth factor receptor; Non small cell lung cancer; Quality of life

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB;

ANOREXIA; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; COUGHING; DYSPNEA; EMOTION; FATIGUE; HUMAN; LUNG NON SMALL CELL CANCER; PHYSICAL CAPACITY; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SHOULDER PAIN; SOCIAL STATUS; SYMPTOM; THORAX PAIN;

EID: 23944525040     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol, 2002, 20(9): 2240-2250.
2. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol, 2002, 20(18): 3815-3825.
3. Herbst RS. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. Semin Oncol, 2003, 30(1 Suppl 1): 30-38.
4. Cella D. Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy-lung scale. Semin Oncol, 2003, 30(1 Suppl 1): 39-48.
5. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst, 1993, 85(5): 365-376.
6. Stephens RJ, Hopwood P, Girling DJ. Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer, 1999, 79(3-4): 538-544.
7. Montazeri A, Gillis CR, McEwen J. Quality of life in patients with lung cancer: a review of literature from 1970 to 1995. Chest, 1998, 113(2): 467-481.
8. Zhao H, Kanda K. Translation and validation of the standard Chinese version of the EORTC QLQ-C30. Qual Life Res, 2000, 9(2): 129-137.